According to the latest documents submitted to the U.S. Securities and Exchange Commission (SEC), biopharmaceutical company Spruce Biosciences, Inc. has been authorized to offer and sell its common stock under the current sales agreement, with the total amount not exceeding the planned maximum limit.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Aave Emerges as a Top Destination for Crypto Yield in Tight Market Conditions

Trending news
MoreLand & Buildings Investment Management released a statement, bluntly pointing out that the board of First Industrial Realty Trust is causing significant losses to shareholders due to its adherence to the status quo and lack of change, estimating a per-share value loss of up to approximately $15.
The US Department of Justice has reached a preliminary settlement with live entertainment giant Live Nation Entertainment regarding antitrust charges, and the details of the agreement have recently been submitted to the court for review.
